Results 171 to 180 of about 323,501 (341)

Serum cytokine profiling differentiates underlying diseases in cytokine storm syndrome

Arthritis &Rheumatology, Accepted Article.
Objective Cytokine storm syndrome (CSS), commonly associated with hemophagocytic lymphohistiocytosis (HLH), is a fatal hyperinflammatory syndrome. Differentiating the underlying diseases responsible for CSS is essential for timely therapeutic decisions. This study explored the clinical usefulness of serum cytokine profiling in distinguishing underlying
Shuya Kaneko, Maho Hatano, Asami Shimbo, Futaba Miyaoka, Hitoshi Irabu, Yuko Akutsu, Yuko Hayashi, Mao Mizuta, Yasuo Nakagishi, Keiji Akamine, Naomi Iwata, Kenji Furuno, Takayuki Tanaka, Kazuyuki Ueno, Shuhei Fujita, Koji Yokoyama, Toshinori Minato, Kazushi Izawa, Takahiro Yasumi, Tadashi Matsubayashi, Tadashi Hosoya, Hiroki Nishikawa, Junya Fujimura, Ryoko Asano, Yuko Sugita, Kenichi Watanabe, Anna Kobayashi, Takuya Endo, Katsuhide Eguchi, Ryuta Nishikomori, Ryuhei Yasuoka, Takaki Asano, Miyako Kanno, Kazuya Hamada, Yuji Fujita, Daisuke Hayashi, Shojiro Watanabe, Takeshi Shiba, Shinsuke Yasuda, Masaaki Mori, Hirokazu Kanegane, Masatoshi Takagi, Masaki Shimizu   +42 more
wiley   +1 more source

IN VITRO RESPONSE OF PERIPHERAL LYMPHOCYTES FROM PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS TO DNA

, 1968
Michihito Okubo
openalex   +2 more sources

Systemic lupus erythematosus. Daniel L. Lorson. M.D. Boston, Little, Brown & Co., 1961, 212 pp., $7.50 [PDF]

, 1961
John H. Talbott
openalex   +1 more source

Epidermal Interferon kappa drives cutaneous lupus‐like lesions, photosensitivity and systemic autoimmunity in vivo

Arthritis &Rheumatology, Accepted Article.
Objective Keratinocyte‐derived interferon kappa (IFN‐κ) is chronically overexpressed in human non‐lesional systemic lupus erythematosus (SLE) skin. Recent evidence suggests that epidermal signals instruct the immune system in SLE, but whether epidermal IFN‐κ alone is sufficient to drive lupus phenotypes has not been investigated.
Benjamin Klein, Deborah J. Colesa, Yiqing Gao, Patrick A. O'Brien, Lin Zhang, Lori Lowe, Kelsey E. McNeely, Nguyen Thi Kim Nguyen, Svenja Henning, Mehrnaz Gharaee‐Kermani, Jeffrey B. Hodgin, Jacob W. S. Martens, Johann E. Gudjonsson, Celine C. Berthier, J. Michelle Kahlenberg   +14 more
wiley   +1 more source

ROS‐induced modifications of fibrin clots connect immune responses to atherothrombosis in systemic lupus erythematosus

Arthritis &Rheumatology, Accepted Article.
Objective Cardiovascular events are major determinants of morbidity and mortality in systemic lupus erythematosus (SLE), particularly in patients with renal involvement. While oxidative stress has been implicated in driving vascular and renal damage in SLE, the specific mechanisms remain unclear.
Matteo Becatti, Giacomo Emmi, Alessandra Bettiol, Amanda Mannucci, Flavia Rita Argento, Eleonora Fini, Serena Borghi, Francesca Nencini, Maria Nicastro, Irene Mattioli, Elena Silvestri, Augusto Vaglio, Domenico Prisco, Claudia Fiorillo   +13 more
wiley   +1 more source

Cytokine pathways driving diverse tissue pathologies in rheumatoid arthritis

Arthritis &Rheumatology, Accepted Article.
Rheumatoid arthritis is a complex systemic disorder characterised primarily by articular inflammation and destruction with associated functional loss and reduced quality of life. RA is also associated with extra‐articular disease e.g. of the lung with potentially devastating clinical consequences.
Aurelie Najm, Lyn D. Ferguson, Iain B. McInnes   +2 more
wiley   +1 more source

Evaluation of damage index and its association with risk factors in patients with systemic lupus erythematosus

Journal of Research in Medical Sciences, 2011
Background: This study aimed to determine the value of damage index in patients with systemic lupus erythematosus (SLE) and the association between damage index and disease severity, flare up numbers, disease duration, and antiphospholipid antibodies ...
Zahra Sayed Bonakdar, Negin Mohtasham, Mansoor Karimifar   +2 more
doaj  

A randomized, placebo‐controlled trial of hydroxychloroquine in incomplete lupus

Arthritis &Rheumatology, Accepted Article.
Objectives Patients with features of systemic lupus erythematosus (SLE) who do not fulfill classification criteria can be designated as incomplete lupus (ILE). This condition includes individuals with a high risk of progression to SLE. Treatment of ILE may reduce symptoms, severity and incidence of SLE. Methods Hydroxychloroquine (HCQ) was chosen as an
Nancy J. Olsen, Duanping Liao, Judith A. James, Joel M. Guthridge, Cristina Arriens, Diane Kamen, Mariko Ishimori, Daniel J. Wallace, Christopher Striebich, Sonali Narain, Benjamin F. Chong, Fan He, Eric W. Schaefer, Vernon M. Chinchilli, David R. Karp   +14 more
wiley   +1 more source

Catatonia in Systemic Lupus Erythematosus. [PDF]

NeuroSci
Manzo C, Serra-Mestres J, Isetta M.
europepmc   +1 more source

Sjögren Disease—B Cells at the Brink: From Autoimmunity to Lymphomagenesis and the Rise of Novel B Cell‐Targeted Therapies

Arthritis &Rheumatology, Accepted Article.
Sjögren disease (SjD) is a common systemic autoimmune disorder characterized by inflammation of the exocrine glands, resulting in dryness. Patients frequently exhibit extraglandular manifestations affecting various organ systems. To date, there are no FDA‐approved disease‐modifying therapies for SjD.
Rachael A. Gordon, Sara S. McCoy
wiley   +1 more source